LipoScience, Inc. : LipoScience Announces Closing of Initial Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares

LipoScience, Inc. (NASDAQ: LPDX) today announced it has closed its previously announced initial public offering of 5,000,000 shares of common stock at a price to the public of $9.00 per share. In connection with the initial public offering, the underwriters exercised in full their option to purchase an additional 750,000 shares from the company. As a result, the total initial public offering size was 5,750,000 shares. LipoScience expects to receive, after deducting underwriting discounts and commissions and estimated offering expenses payable by the company, net proceeds of approximately $44.9 million from the offering.

Barclays Capital Inc., UBS Securities LLC and Piper Jaffray & Co. acted as joint book-running managers for the offering.

The offering of these securities was made only by means of a prospectus. A copy of the prospectus may be obtained from the offices of Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [e-mail] or by phone at [phone]; UBS Securities LLC, Attention: UBS Prospectus Department, 299 Park Avenue, 28th Floor, New York, NY 10019 or by phone at [phone]; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at [phone] or by email at [e-mail].

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on January 24, 2013.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About LipoScience, Inc.

LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile^® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 8 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera^® has been cleared by the FDA and will be placed with national and regional clinical laboratories. LipoScience is driving toward a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.

Investor Relations
ICR, Inc.
Bob Yedid, 646-277-1250
Senior Vice President
[e-mail]
or
LipoScience, Inc.
Tori Hall, 919-256-1046
[e-mail]